Skip to main content

Table 2 Demographic and clinical characteristics of patients who had a diagnosis of laboratory-confirmed RR-TB reported to the COJ for tracing between July 2011–June 2012 (n = 594) and July 2013–June 2014 (n = 713) and those included in the treatment outcomes sub-study (n = 537)

From: Impact of Xpert MTB/RIF and decentralized care on linkage to care and drug-resistant tuberculosis treatment outcomes in Johannesburg, South Africa

Characteristic   Early (n = 594) Late (n = 713) Included in sub-analysis (n = 537)
Gender n, %    
 Male   307 (51.6) 397 (55.6) 279 (51.9)
 Female   287 (48.3) 316 (44.3) 258 (48.0)
Age, years Median, IQR 34 (29–42) 37 (30–44) 36 (29–43)
  < 30   162 (27.3) 161 (22.6) 138 (25.7)
 30–45   308 (51.9) 376 (52.7) 282 (52.5)
 45–60   105 (17.6) 159 (22.3) 106 (19.7)
  ≥ 60   19 (3.2) 17 (2.4) 11 (2.1)
DR-TB classification n, %    
 RR-TB by Xpert MTB/RIF   158 (26.6) 316 (44.3) 237 (44.1)
 RIF mono-resistant TB   102 (17.2) 130 (18.2) 109 (20.3)
 MDR-TB   320 (53.8) 262 (36.8) 191 (35.6)
 XDR-TB   14 (2.4) 5 (0.7) n/a
Sputum collection to diagnosis, days Median, IQR 26 (7–36) 2 (1–7) 13 (7–28)
Diagnosis method from the COJ register n, %    
 Xpert MTB/RIF   258 (43.4) 431 (60.5) 337 (62.8)
 Geno Type MTBDR plus line probe assay   281 (47.3) 242 (33.9) 172 (32.0)
 Phenotypic drug sensitivity testing   30 (5.1) 2 (0.3) 6 (1.1)
 Unknown   25 (4.2) 38 (5.3) 22 (4.1)
AFB smear microscopy n, %    
 Positive   144 (24.3) 119 (16.7) 94 (17.4)
 Negative   78 (13.1) 49 (6.9) 44 (8.2)
 Unknown   372 (62.6) 545 (76.4) 400 (74.4)
HIV status at initiation n, %    
 Positive   155 (26.1) 336 (47.1) 428 (79.7)
  HIV positive on ART   n/a n/a 351/428 (82.0)
  HIV positive not on ART   n/a n/a 77/428 (17.9)
 HIV Negative   24 (4.0) 78 (10.9) 61 (11.4)
 Unknown   415 (69.9) 299 (42.0) 48 (8.9)
Time on ART, months Median, IQR    
 ART initiation before TB treatment initiation (n = 171)   n/a n/a 9.6 (3.1–27.4)
 ART initiation after TB treatment initiation (n = 117)   n/a n/a 0.5 (0.4–0.9)
  1. MDR-TB Multi-drug resistant, XDR-TB Extensively drug resistant TB, RR-TB Rifampicin resistant TB, AFB Acid fast bacilli, ART antiretroviral therapy, DR-TB drug resistant TB, RIF rifampicin